Agilent Technologies, Inc. · NYSE:A

Agilent Technologies — Q1 2023 Earnings Presentation

9 slides from Agilent Technologies's earnings presentation, Feb 28, 2023

  1. Slide 1: Agilent Technologies Q1'23 Financial Results Overview

    Agilent Technologies Q1’23 Financial Results Overview

  2. Slide 2: Safe Harbor

    Safe Harbor These presentations contain forward-looking statements (including, without limitation, information, and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth

  3. Slide 3: Agilent Results Q1'23

    Agilent Results Q1’23 A leading lab partner with unsurpassed capabilities and scale Q1’23 Financial Metrics Q1’23 Highlights • Revenues: $1.76B, +4.9% reported, • Growth: Continued strong results in Pharma and broad strength in the applied +10.1% y/y core(1)(2) (-5.3% FX,+0.1% M&A). markets drove 10

  4. Slide 4: Growth in a $68B+ Market – Q1'23 Core Growth Results by End Market

    Growth in a $68B+ Market – Q1’23 Core Growth(2) Results by End Market Continued momentum in Pharma and CAM supported by robust growth in Food and Environmental & Forensics  Pharma & Biotech: Up 11% with strength across large and small molecule globally.  Chemicals & Advanced Materials: Up 14% driv

  5. Slide 5: Life Sciences & Applied Markets Group (LSAG)

    Life Sciences & Applied Markets Group (LSAG) • Q1 core revenue growth of +11% for LSAG was Instrumentation, Informatics, and Consumables driven by the Chemicals and Advanced materials for Analytical Laboratories market, as demand for semis and batteries continues to drive customers to invest. On a p

  6. Slide 6: Agilent CrossLab Group (ACG)

    Agilent CrossLab Group (ACG) • CrossLab continued to deliver superior Analytical Laboratory Services results in Q1, growing 13% core on top of a 10%(1)(2) Y/Y compare. The team’s deep knowledge of customer-lab operations continues to drive service business growth as the breadth and diversity of its

  7. Slide 7: Diagnostics and Genomics Group (DGG)

    Diagnostics and Genomics Group (DGG) • Q1 core revenue growth of 5% was driven by NASD and IHC cancer diagnostics. Pathology, Genomics, and Nucleic Acid Manufacturing • Announced a ~$725 million investment to double manufacturing capacity of therapeutic nucleic acids in response to rapid growth of t

  8. Slide 8: Q2'23 and FY'23 Guidance and Forward-looking Considerations

    Q2’23 and FY’23 Guidance and Forward-looking Considerations Based on Forecasted Exchange Rates Q2’23 Guidance (1) FY’23 Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,655 $1,680 Net Revenue ($M) $7,030 $7,100 Y/Y Core Revenue Growth (2) 6.0% 7.5% Y/Y Core Revenue Growth (2) 5.5%

  9. Slide 9: Q1'23 Financial Results Overview

    2/28/2023 Q1'23 Financial Results Overview

Agilent Technologies — Q1 2023 Earnings Presentation on 6ix